Business context and reporting period
The supplied filing is Visualant, Inc.’s Form 10-K for the fiscal year ended September 30, 2017—not a filing identified as USBC, Inc. The requested company and filing registrant therefore do not match. This is an annual report, not a standalone fourth-quarter report; financial comparisons below are fiscal 2017 versus fiscal 2016. Visualant traded on the OTCQB as VSUL.
Visualant develops ChromaID, a light-based substance identification and authentication technology, and is pursuing commercialization through products, licensing, and partners. Its TransTech Systems distribution business generated substantially all company revenue; ChromaID revenue remained minimal.
Financial performance and condition
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $4.874 million | $6.024 million |
| Gross profit and margin | $0.908 million; 18.6% | $0.988 million; 16.4% |
| Operating loss | $3.243 million | $2.693 million |
| Net loss | $3.901 million | $1.746 million |
| Basic and diluted loss per share | $1.01 | $1.22 |
| Net cash used in operating activities | $1.264 million | $2.746 million |
| Cash at fiscal year-end | $103,181 | $188,309 |
Revenue fell 19.1%, primarily because TransTech had lower product sales and did not repeat a large prior-year sale. Gross profit dollars declined, although gross margin improved. The larger net loss reflected, among other items, a $983,645 goodwill impairment and a swing in non-operating results: FY 2016 included a substantial noncash derivative-related gain, while FY 2017 reported other expense.
At September 30, 2017, current assets were $1.050 million and current liabilities were $5.149 million, producing a reported working-capital deficit of approximately $4.099 million. Stockholders’ deficit was $3.961 million and accumulated deficit was $31.534 million. The balance sheet included $1.166 million of current notes and secured debt and $570,000 of current convertible notes. The filing also reports $1.571 million owed to the CEO or affiliated entities, including notes, advances, and unreimbursed expenses or compensation; this amount should not be added to debt without checking its component classifications.
Operating cash use improved year over year, but financing provided $1.145 million in FY 2017 and cash still declined by $85,128. Capital resources included $690,000 of convertible-note proceeds, $550,000 from common and preferred stock issuance, and $30,321 from a credit line. The filing states that available cash was expected to fund operations only through January 31, 2018.
Material changes, outlook, and risks
- TransTech goodwill was fully impaired, with a $983,645 charge, following management’s assessment of the business and its financial constraints. Research and development spending fell to $79,405 from $325,803; the filing attributes the decrease to lower commercialization-related spending and the end of services from RATLab.
- Management described ChromaID as moving toward commercialization, including internal product development and work with Intellicheck and BioMedx. It reported interest from potential partners, but these relationships had not generated significant revenue. No quantified revenue or profitability guidance is provided.
- The auditor’s report and management disclosures state that recurring losses, negative operating cash flow, a substantial working-capital deficit, and the need for financing raise substantial doubt about the company’s ability to continue as a going concern. Management said additional financing was necessary; failure to obtain it could require restructuring, asset divestitures, or bankruptcy.
- After year-end, the company disclosed a December 2017 financing in which it received $250,000 and issued a $300,000 senior convertible debenture with a warrant to purchase 1.2 million shares. The filing also describes an August 2017 debenture with a 20% interest rate, a $0.25 initial conversion price, warrants, and security over substantially all company assets, subject to the stated lien-termination condition. These securities create material repayment, collateral, and dilution considerations.
- Potential dilution is substantial: the filing lists 6.900 million warrants, 2.825 million shares issuable on preferred-stock conversion, 332,940 placement-agent warrant shares, and convertible debentures whose share count is not specified. Preferred and warrant conversion or exercise terms were reset to $0.25 in August 2017, subject to adjustments.
- Management concluded internal control over financial reporting and disclosure controls were ineffective, citing the absence of an audit committee financial expert, late SEC filings, and insufficient segregation of financial-reporting duties. The filing reports no non-routine pending legal proceeding.
Key investor verification points
- Confirm the issuer identity: the provided document is Visualant, Inc.’s 10-K, not USBC, Inc.’s filing.
- Review the audited statements and subsequent-event disclosures for current cash, financing availability, debt maturities, defaults, collateral priorities, and the status of the going-concern funding plan.
- Reconcile related-party obligations, including the reported $1.571 million owed to the CEO and affiliates, against the debt and accrued-liability line items.
- Assess the full potential dilution and priority rights from debentures, preferred stock, warrants, and any further financing; verify actual conversion terms and share counts.
- Evaluate whether ChromaID commercialization produces meaningful, recurring revenue and whether TransTech can stabilize sales and margins; verify remediation of the disclosed control weaknesses.